-$1.49 EPS Expected for Radius Health Inc (RDUS) This Quarter

Brokerages forecast that Radius Health Inc (NASDAQ:RDUS) will post ($1.49) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Radius Health’s earnings, with the highest EPS estimate coming in at ($1.42) and the lowest estimate coming in at ($1.56). Radius Health reported earnings of ($1.22) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 22.1%. The business is expected to report its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that Radius Health will report full year earnings of ($5.62) per share for the current fiscal year, with EPS estimates ranging from ($5.77) to ($5.30). For the next year, analysts anticipate that the firm will post earnings of ($5.05) per share, with EPS estimates ranging from ($5.98) to ($3.91). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Radius Health.

Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the prior year, the business posted ($1.07) earnings per share.

A number of brokerages recently commented on RDUS. BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $58.00 price objective on shares of Radius Health in a research report on Thursday. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Citigroup began coverage on shares of Radius Health in a research report on Wednesday, December 6th. They set a “neutral” rating and a $30.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the stock. Radius Health currently has an average rating of “Hold” and an average target price of $48.00.

Radius Health (RDUS) opened at $38.02 on Friday. The firm has a market cap of $1,610.66, a P/E ratio of -7.00 and a beta of 1.10. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16.

In other Radius Health news, VP Brent Hatzis-Schoch bought 1,778 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was bought at an average cost of $28.09 per share, with a total value of $49,944.02. Following the completion of the transaction, the vice president now directly owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was acquired at an average cost of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the transaction, the insider now directly owns 5,698,799 shares of the company’s stock, valued at $149,593,473.75. The disclosure for this purchase can be found here. Insiders acquired 158,578 shares of company stock valued at $4,659,916 over the last three months. Insiders own 15.00% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in Radius Health in the third quarter worth approximately $110,000. Ameritas Investment Partners Inc. grew its position in Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 541 shares in the last quarter. Advisor Group Inc. grew its position in Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares in the last quarter. Amalgamated Bank bought a new stake in Radius Health in the second quarter worth approximately $211,000. Finally, Principal Financial Group Inc. grew its position in Radius Health by 14.1% in the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 839 shares in the last quarter.

WARNING: “-$1.49 EPS Expected for Radius Health Inc (RDUS) This Quarter” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/20/1-49-eps-expected-for-radius-health-inc-rdus-this-quarter.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply